News

Care’s brands include the Fess line of cold/allergy and saline nasal health products, Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Financial details

This announcement comes, following a strategic alliance inked on 26 June 2013 between Cha and Pluristem Therapeutics, which is a developer of placenta-based cell therapies. As per the

The collaboration with Advance Trading, which is a distributor of PAS in the country, will enable Rafarma to increase production capacity of PAS and establish itself as one

Out of the funding, nearly €4.3m has been given directly to BioAlliance Pharma to hasten the industrial development of Livatag, a doxorubicin nanoparticle currently under phase III trial

Cancer Research UK policy and information executive director Sarah Woolnough said that the initiative should help save more lives from cancer in the future. "Crucially, it means unearthing

Commencement of the study using the platform has triggered a milestone payment for BioInvent, as per its collaboration agreement with partners who finance the development of the new

Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of

Developed under a co-development and commercialization agreement between Genmab and GSK, Ofatumumab is a human monoclonal antibody which targets an epitope on the CD20 molecule encompassing parts of

A clotting factor, Eloctate is under development using Biogen Idec’s novel and proprietary monomeric Fc fusion technology. Announced at the XXIV International Society on Thrombosis and Haemostasis (ISTH)